Anadys Looks To Head Of Class In HCV Polymerase Inhibitors With Setrobuvir
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Anadys Pharmaceuticals, Inc. is staying mum about its partnering prospects, but the biotech clearly thinks promising Phase IIb data for setrobuvir (ANA598), its polymerase inhibitor for genotype 1 hepatitis C, could move it to the head of the class.
You may also be interested in...
Pharmasset: A Breakout Year But Big Catalysts Lie Ahead
Although only half over, 2011 already has been pivotal for hepatitis C drug development, with the launch of two paradigm-shifting protease inhibitors, Johnson & Johnson/Vertex Pharmaceuticals Inc.'s Incivek (telaprevir) and Merck & Co.'s Victrelis (boceprevir). Both hit the market in May, even as attention is now shifting to the next big advance in HCV. Based on its work on next-gen HCV treatment, Pharmasset, Inc. has captivated the investment community.
Anadys HCV Drug Is On Track For Phase II, But Rash In Healthy-Volunteer Study Pummels Stock
ANA598 viral-load reduction is not enough to take away investors’ worry.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.